Rejuvenation Technologies Inc.
mRNA therapeutics to extend healthspan entering clinical trials
What they do
Age-related telomere shortening limits healthspan and contributes to organ system decline.
An mRNA therapeutic drug platform designed to lengthen telomeres and improve healthspan, moving from preclinical results into clinical trials.
Clinicians and clinical researchers running investigator-initiated trials, ultimately treating patients with age-related decline.
Founders
Stanford PhD Genetics (2018)
John Ramunas, PhD, invented TERT mRNA telomere extension at Stanford in Helen Blau's lab — reversing a decade of telomere shortening in one treatment. 50+ granted patents across 7 families through 2046. Preclinical efficacy in 4 organ systems. FDA INTERACT cleared. Khosla Ventures seed. YC S18. Raising $10M seed extension ($2M wired) for 3 clinical trials — Phase I readout Q3 2027. Subject #1 in first human trial.
Company timeline
- Founded2016
- YC batchSummer 2018
- StatusActive
- Team size2 people
- LocationSan Francisco, CA, USA
Similar startups
